EP1412374A4 - Nouveaux isoformes de pgc-1 et applications de ceux-ci - Google Patents

Nouveaux isoformes de pgc-1 et applications de ceux-ci

Info

Publication number
EP1412374A4
EP1412374A4 EP02749811A EP02749811A EP1412374A4 EP 1412374 A4 EP1412374 A4 EP 1412374A4 EP 02749811 A EP02749811 A EP 02749811A EP 02749811 A EP02749811 A EP 02749811A EP 1412374 A4 EP1412374 A4 EP 1412374A4
Authority
EP
European Patent Office
Prior art keywords
pgc
nucleic acid
acid molecules
isoforms
expression vectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP02749811A
Other languages
German (de)
English (en)
Other versions
EP1412374B1 (fr
EP1412374A2 (fr
Inventor
Bruce M Spiegelman
Guillaume Adelmant
Pere Puigserver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of EP1412374A2 publication Critical patent/EP1412374A2/fr
Publication of EP1412374A4 publication Critical patent/EP1412374A4/fr
Application granted granted Critical
Publication of EP1412374B1 publication Critical patent/EP1412374B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
EP02749811A 2001-07-05 2002-07-03 Nouveaux isoformes de pgc-1 et applications de ceux-ci Expired - Lifetime EP1412374B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30346801P 2001-07-05 2001-07-05
US303468P 2001-07-05
PCT/US2002/021337 WO2003004613A2 (fr) 2001-07-05 2002-07-03 Nouveaux isoformes de pgc-1 et applications de ceux-ci

Publications (3)

Publication Number Publication Date
EP1412374A2 EP1412374A2 (fr) 2004-04-28
EP1412374A4 true EP1412374A4 (fr) 2005-07-20
EP1412374B1 EP1412374B1 (fr) 2010-09-08

Family

ID=23172241

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02749811A Expired - Lifetime EP1412374B1 (fr) 2001-07-05 2002-07-03 Nouveaux isoformes de pgc-1 et applications de ceux-ci

Country Status (8)

Country Link
US (2) US7250283B2 (fr)
EP (1) EP1412374B1 (fr)
JP (1) JP4495961B2 (fr)
AT (1) ATE480620T1 (fr)
AU (1) AU2002320301A1 (fr)
CA (1) CA2451395C (fr)
DE (1) DE60237613D1 (fr)
WO (1) WO2003004613A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068944A2 (fr) * 2002-02-13 2003-08-21 Dana-Farber Cancer Institute, Inc. Methodes et compositions permettant de moduler la formation de fibres musculaires de type i a l'aide de pgc-1?-
WO2005093068A1 (fr) * 2004-03-29 2005-10-06 Dainippon Sumitomo Pharma Co., Ltd. Nouvelle proteine et nouveau promoteur
EP1774028A4 (fr) * 2004-07-07 2008-05-07 Dana Farber Cancer Inst Inc Procédés et compositions pour le traitement de l'obésite
JP4936476B2 (ja) * 2005-06-28 2012-05-23 第一三共株式会社 Ｌｘｒリガンドの試験方法
US8858990B2 (en) 2009-09-17 2014-10-14 The Ohio State University Capsule of thermogenic cells for treating a metabolic disease
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
US8476227B2 (en) 2010-01-22 2013-07-02 Ethicon Endo-Surgery, Inc. Methods of activating a melanocortin-4 receptor pathway in obese subjects
WO2014138338A1 (fr) 2013-03-06 2014-09-12 The General Hospital Corporation Compositions combinatoires et méthodes de traitement d'un mélanome
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032215A1 (fr) * 1998-12-01 2000-06-08 Dana-Farber Cancer Institute PGC-1: UN COACTIVATEUR DU RECEPTEUR PPARη DES TISSUS ADIPEUX BRUNS
US6166192A (en) * 1997-05-30 2000-12-26 Dana-Farber Cancer Institute PGC-1, a novel brown fat PPARγ coactivator

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001035096A2 (fr) * 1999-11-10 2001-05-17 Mitokor Modulation de la masse et de la fonction mitochondriales permettant de traiter des maladies, et de cibler et de decouvrir des medicaments

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166192A (en) * 1997-05-30 2000-12-26 Dana-Farber Cancer Institute PGC-1, a novel brown fat PPARγ coactivator
WO2000032215A1 (fr) * 1998-12-01 2000-06-08 Dana-Farber Cancer Institute PGC-1: UN COACTIVATEUR DU RECEPTEUR PPARη DES TISSUS ADIPEUX BRUNS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 11 January 2000 (2000-01-11), "Homo sapiens chromosome 3p clone RP11-1004L19, WORKING DRAFT SEQUENCE, 8 unordered pieces.", XP002329206, retrieved from EBI accession no. EM_PRO:AC020746 Database accession no. AC020746 *

Also Published As

Publication number Publication date
CA2451395A1 (fr) 2003-01-16
EP1412374B1 (fr) 2010-09-08
US20040254362A1 (en) 2004-12-16
US20090098569A1 (en) 2009-04-16
ATE480620T1 (de) 2010-09-15
US7250283B2 (en) 2007-07-31
JP2004533842A (ja) 2004-11-11
WO2003004613A2 (fr) 2003-01-16
DE60237613D1 (de) 2010-10-21
EP1412374A2 (fr) 2004-04-28
JP4495961B2 (ja) 2010-07-07
WO2003004613A3 (fr) 2003-11-20
AU2002320301A1 (en) 2003-01-21
CA2451395C (fr) 2015-11-24

Similar Documents

Publication Publication Date Title
MXPA02001878A (es) Moleculas b7-4 novedosas y usos de las mismas.
DE60035517D1 (de) Gl50 moleküle, sowie verwendungen derselben
WO2003042362A8 (fr) Pgc-1$g(b), un nouvel homologue du pgc-1 et leurs utilisations
WO2001087978A3 (fr) La 38594, nouveau transporteur humain et ses utilisations
WO2001096392A8 (fr) Molecules 22109, constituant un nouveau membre de la famille des thioredoxines humaines et utilisations correspondantes
EP1412374A4 (fr) Nouveaux isoformes de pgc-1 et applications de ceux-ci
WO2002002760A3 (fr) 25869, nouvelle carboxylesterase humaine et ses utilisations
WO2002016591A3 (fr) 49937, 49931, et 49933, nouveaux elements de la famille des transporteurs humains et utilisation de ces derniers
AU2001280639A1 (en) 13237,18480,2245 or 16228 human protein kinase molecules and uses therefor
AU2001249649A1 (en) 16836, a novel human phospholipase c family member and uses thereof
WO2001064905A3 (fr) 2504, 15977 et 14760, nouveaux membres de la famille proteine kinase et leurs utilisations
AU2001285204A1 (en) Atcr-1, a human acyltransferase and uses thereof
AU2002352068A1 (en) 2150, a human protein kinase family member and uses therefor
AU2002359572A8 (en) 15603, a human ion channel family member
WO2001079293A3 (fr) 57809 et 57798, nouvelles molecules de cadherine humaines et utilisations
WO2002029037A3 (fr) 57800, nouvelle cadherine humaine et ses applications
WO2003035840A3 (fr) 69583 et 85924, nouveaux membres d'une famille de proteine kinase humaine et utilisations associees
WO2002010401A3 (fr) 18431 et 32374, elements de la famille des proteine kinases humaines et utilisations correspondantes
WO2002079379A3 (fr) Membre de la famille de glycosyltransferase humaine appele 47153 et ses utilisations
WO2002064815A3 (fr) 33945, membre de la famille de glycosyltransferase humaine, et ses utilisations
WO2002057226A8 (fr) Molecules de proteine kinase 68730 et 69112, et leurs utilisations
WO2002016616A3 (fr) 33410, nouveau membre de la famille de la carboxylesterase humaine et ses utilisations
WO2002076174A3 (fr) Fbh58295fl, nouveau transporteur d'acide amine humain et utilisations associees
AU2001257405A1 (en) 14911 novel protein kinase molecules and uses therefor
WO2002002602A3 (fr) Nouvelle proteine slgp et nouvelles molecules d'acide nucleique et leurs utilisations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040205

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PUIGSERVER, PERE

Inventor name: SPIEGELMAN, BRUCE, M.

Inventor name: ADELMANT, GUILLAUME

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 14/47 B

Ipc: 7C 12Q 1/68 B

Ipc: 7C 12N 15/12 A

Ipc: 7C 07K 16/18 B

Ipc: 7G 01N 33/50 B

Ipc: 7C 12N 5/10 B

Ipc: 7G 01N 33/53 B

Ipc: 7C 12N 15/63 B

A4 Supplementary search report drawn up and despatched

Effective date: 20050603

17Q First examination report despatched

Effective date: 20060216

17Q First examination report despatched

Effective date: 20060216

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: HEPP WENGER RYFFEL AG

REF Corresponds to:

Ref document number: 60237613

Country of ref document: DE

Date of ref document: 20101021

Kind code of ref document: P

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20100908

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100908

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100908

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100908

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100908

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101209

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100908

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100908

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100908

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110110

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100908

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100908

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100908

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101219

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20110609

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100908

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60237613

Country of ref document: DE

Effective date: 20110609

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110731

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110703

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110703

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101208

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100908

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20210727

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20210727

Year of fee payment: 20

Ref country code: CH

Payment date: 20210804

Year of fee payment: 20

Ref country code: DE

Payment date: 20210728

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 60237613

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20220702

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20220702